TD Cowen Has Lowered Expectations for Globe Life (NYSE:GL) Stock Price

by · The Markets Daily

Globe Life (NYSE:GL – Get Free Report) had its target price lowered by stock analysts at TD Cowen from $225.00 to $215.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price objective indicates a potential upside of 30.47% from the company’s previous close.

A number of other research analysts have also recently issued reports on GL. Morgan Stanley cut their price objective on Globe Life from $208.00 to $197.00 and set an “overweight” rating for the company in a report on Monday, October 5th. Wells Fargo & Company raised their target price on Globe Life from $190.00 to $191.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Piper Sandler cut Globe Life from an “overweight” rating to a “neutral” rating and set a $165.00 price target for the company. in a report on Friday. Jefferies Financial Group increased their price objective on shares of Globe Life from $147.00 to $166.00 and gave the stock a “hold” rating in a report on Friday, July 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Globe Life from $193.00 to $195.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $182.60.

Get Our Latest Analysis on GL

Globe Life Price Performance

NYSE GL opened at $164.79 on Friday. The company has a current ratio of 0.07, a quick ratio of 0.07 and a debt-to-equity ratio of 0.43. The company has a fifty day simple moving average of $170.48 and a 200 day simple moving average of $167.25. The company has a market cap of $12.66 billion, a P/E ratio of 11.02 and a beta of 0.44. Globe Life has a 1 year low of $127.85 and a 1 year high of $191.55.

Globe Life (NYSE:GL – Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.90 by ($0.06). The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.56 billion. Globe Life had a return on equity of 19.95% and a net margin of 18.89%. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.81 earnings per share. On average, sell-side analysts predict that Globe Life will post 15.70 EPS for the current year.

Globe Life declared that its board has authorized a stock repurchase plan on Monday, August 10th that authorizes the company to buy back $2.50 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 17.7% of its shares through open market purchases. Share repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Insider Activity

In other Globe Life news, CFO Thomas Kalmbach sold 21,000 shares of Globe Life stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $180.06, for a total transaction of $3,781,260.00. Following the transaction, the chief financial officer directly owned 50,568 shares in the company, valued at approximately $9,105,274.08. The trade was a 29.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James Darden sold 50,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $182.43, for a total transaction of $9,121,500.00. Following the sale, the chief executive officer owned 58,451 shares in the company, valued at approximately $10,663,215.93. The trade was a 46.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 143,650 shares of company stock valued at $25,793,717. 2.11% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Globe Life

Several institutional investors and hedge funds have recently modified their holdings of the stock. Root Financial Partners LLC bought a new position in shares of Globe Life during the third quarter worth approximately $92,000. Mayfair Advisory Group LLC boosted its holdings in shares of Globe Life by 37.3% in the 3rd quarter. Mayfair Advisory Group LLC now owns 6,092 shares of the company’s stock valued at $1,009,000 after purchasing an additional 1,654 shares in the last quarter. CWA Asset Management Group LLC lifted its holdings in shares of Globe Life by 10.9% in the third quarter. CWA Asset Management Group LLC now owns 45,985 shares of the company’s stock worth $7,617,000 after acquiring an additional 4,502 shares during the last quarter. Counterpoint Mutual Funds LLC bought a new stake in shares of Globe Life during the third quarter worth $265,000. Finally, USA Financial Formulas acquired a new stake in shares of Globe Life during the third quarter valued at about $576,000. 81.61% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Globe Life

Here are the key news stories impacting Globe Life this week:

  • Positive Sentiment: Globe Life reported third-quarter revenue of approximately $1.60 billion, above the $1.56 billion analyst consensus, with revenue up 5.5% year over year. Operating EPS increased to $4.84 from $4.81 a year earlier. Globe Life third-quarter 2026 results
  • Positive Sentiment: Management is targeting $850 million to $950 million in parent excess cash flow for 2027, which could support capital returns, debt reduction or other shareholder-friendly actions. The company projects 2027 EPS of $16.10 to $17.10, a range that includes the $16.51 consensus estimate. Globe Life 2027 outlook
  • Neutral Sentiment: The company’s 2027 EPS guidance of $16.10 to $17.10 implies continued earnings growth, but the broad range suggests uncertainty around operating performance and future underwriting results.
  • Negative Sentiment: Third-quarter operating EPS of $4.84 missed estimates ranging from $4.87 to $4.90. Weaker underwriting income and higher expenses offset gains from increased premiums and investment income. Globe Life Q3 earnings miss
  • Negative Sentiment: Globe Life cut its FY 2026 EPS outlook to $15.35-$15.65, below the $15.72 consensus estimate. Reports also cited losses at Evry Health as a factor pressuring the full-year guidance. Evry Health losses and Globe Life guidance
  • Negative Sentiment: The quarter included a reported underwriting loss of about $6.4 million, raising investor concerns about claims trends, expense control and the company’s ability to convert premium growth into profits. Globe Life underwriting loss analysis

Globe Life Company Profile

(Get Free Report)

Globe Life Inc (NYSE: GL) is an insurance holding company that provides individual life and supplemental health insurance products through a network of wholly owned subsidiaries. Its offerings are designed primarily for middle-income households and include term and whole life insurance, mortgage protection coverage, accident and supplemental health insurance, Medicare supplement policies, and annuities.

The company markets its products through several distribution channels, including exclusive and independent agency networks, direct-to-consumer sales, and workplace or union-affiliated programs.

Recommended Stories